US Senator Grassley urges White House to finish Sunshine Act regulations
US Senator Chuck Grassley (Republican, Iowa) is urging the White House to finalize the Physician Payments Sunshine Act regulations that will disclose the financial relationships between pharmaceutical and medical device companies and doctors.
Congress designed the law so that the data would be publicly available by September 30, 2013,” Sen Grassley wrote to White House chief of staff Jacob Lew, adding: “Unfortunately, the final regulations are now more than 15 months overdue. At best, the public may miss an entire year’s worth of data collection - perhaps more. This is unacceptable.”
The letter continued: “I urge you to release these final rules without further delay. If the regulations are not going to be released by January 24, 2013, then please provide a date by which they will be issued and an explanation for the delay.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze